Archive for May 14th, 2012

VTUS releases Phase 3 data. Pipeline updates for ATHX and MDGN

May 14, 2012 No Comments by

Ventrus Biosciences, Inc. (Nasdaq:VTUS) today reported positive results from its Phase 3 trial of diltiazem hydrochloride cream (VEN 307) in patients with anal fissures.  Both 4% and 2% diltiazem treatment arms demonstrated significant improvements compared to placebo in the primary endpoint of average of worst anal pain associated with or following defecation (pain score improvement 0.44, […]

Daily News Read more